asa statement glp-1 New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review

Glucagon‐Like Peptide‐1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction

29.71

★★★★☆4.8 (126)

How should we approach patients on GLP-1 agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the Guidelines and Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like

23.33

★★★★★4.9 (98)

FDA proposes a new GLP-1 compounding crackdown

23.07

★★★★★5.0 (157)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

22.70

★★★★★4.7 (84)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

24.12

★★★★★4.9 (203)

The FDA recently published updates clarifying policies for compounding drug manufacturers producing GLP-1 medications post drug shortage. In this post, Dr. Brian LaMar explains what those updated guidelines mean, why Parkview Weight

24.55

★★★★★5.0 (176)

🚨 Regulatory tightening is expanding beyond cannabinoids. With the FDA officially ending the GLP-1 shortage designation, the compounding loophole for certain peptide medications is closing triggering patent enforcement, compliance scrutiny, and market

25.47

★★★★★4.8 (132)